Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company’s investigational RNA interference (RNAi) ...

Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA ...

Biogen ( NASDAQ: BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ( (RNAi)) therapies ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including ...

The expression of symptoms of viral infections is a byproduct of complex virus-host molecular pathways. These remain largely ...

TransCode Therapeutics (NASDAQ: RNAZ) , has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of A ...

The molecular pathways involved in antiviral defenses and counter-defenses in host-pathogen systems remain unclear. Researchers have used Neurospora crassa as a model organism to explore how RNA ...

Several genetic studies have attempted to explore the fungal factors involved in antiviral responses, but the exact genes and ...

Biotech major Biogen (Nasdaq: BIIB) and fellow Cambridge, USA-based City Therapeutics, today announced a strategic ...